Highlight
The G-MASLD study, involving 17,792 MASLD patients across 41 countries, assessed the global performance of non-invasive tests (NITs) to diagnose liver fibrosis stages. Key highlights include: 1) Significant regional variation in the diagnostic accuracy of common NITs such as FIB-4, ELF, and LSM for detecting advanced liver fibrosis and cirrhosis; 2) Agile-3+ and Agile-4 composite scores demonstrated superior and consistent diagnostic performance worldwide; 3) Non-invasive tests still show limitations, particularly in North America and Latin America, indicating the need for region-specific adaptation or further refinement of NIT algorithms.
